ALCOX — Nicox SA Share News
0.000.00%
Last trade - 00:00- €32.43m
- €28.69m
- €16.77m
Brief: Nicox End-June Cash And Cash Equivalents At EUR 31.6 Mln
Brief: Nicox To Publish NCX 470 Results
Brief: Nicox Accelerates Topline Results From NCX 470 Mont Blanc Phase 3 Glaucoma Trial To November 2022
Brief: Nicox To Appoint Andreas Segerros As CEO
Brief: Nicox Q1 Net Revenue At EUR 0.7 Million
Brief: Nicox Says NCX 470 Dolomites Phase 2 Results Published In Journal Of Glaucoma
Brief: Nicox Says Ocumension Get Positive Phase 3 Clinical Trial Results For Zerviate In China
Brief: Nicox Says Vyzulta Now Commercialized In 7 Territories And Approved In Further 9 Countries
Brief: Nicox Granted New Patent For NCX 4251 In Japan
Brief: Nicox Granted New Patent For NCX 470 In China
Brief: Nicox Q4 Net Revenue Down At 3.5 Million Euros
Brief: Nicox European Patent Seals ZERVIATE Major Market Coverage To 2030
Brief: Nicox Says First Patient Screened In China For Denali Trial
Brief: Nicox Raises 15 Million Euros In Private Placement
Brief: Nicox Announces Positive Post Hoc Results From NCX 4251 Phase 2b Mississippi Trial
Brief: Nicox Q3 Net Revenue At 2.4 Million Euros
Brief: Nicox: NCX 470 shows retinal cell protection in a nonclinical model
Brief: Nicox H1 Net Loss Narrows To EUR 11.7 Million
Brief: Nicox: Results From NCX 4251 Phase 2b Mississippi Blepharitis Trial Did Not Meet Primary Or Secondary Efficacy Endpoints